nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—CYP2C8—Montelukast—chronic obstructive pulmonary disease	0.13	0.285	CbGbCtD
Trametinib—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0916	0.201	CbGbCtD
Trametinib—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0619	0.136	CbGbCtD
Trametinib—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.059	0.13	CbGbCtD
Trametinib—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0526	0.116	CbGbCtD
Trametinib—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0309	0.0679	CbGbCtD
Trametinib—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0292	0.0641	CbGbCtD
Trametinib—MAP2K1—respiratory system—chronic obstructive pulmonary disease	0.00648	0.167	CbGeAlD
Trametinib—MAP2K2—respiratory system—chronic obstructive pulmonary disease	0.00571	0.147	CbGeAlD
Trametinib—MAP2K1—connective tissue—chronic obstructive pulmonary disease	0.00571	0.147	CbGeAlD
Trametinib—MAP2K1—smooth muscle tissue—chronic obstructive pulmonary disease	0.00522	0.134	CbGeAlD
Trametinib—MAP2K2—bronchus—chronic obstructive pulmonary disease	0.0047	0.121	CbGeAlD
Trametinib—MAP2K2—smooth muscle tissue—chronic obstructive pulmonary disease	0.0046	0.118	CbGeAlD
Trametinib—MAP2K1—lung—chronic obstructive pulmonary disease	0.00344	0.0885	CbGeAlD
Trametinib—MAP2K2—lung—chronic obstructive pulmonary disease	0.00303	0.078	CbGeAlD
Trametinib—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.000781	0.00299	CcSEcCtD
Trametinib—Haemoglobin—Salbutamol—chronic obstructive pulmonary disease	0.000774	0.00296	CcSEcCtD
Trametinib—Haemorrhage—Salbutamol—chronic obstructive pulmonary disease	0.00077	0.00295	CcSEcCtD
Trametinib—Cough—Tiotropium—chronic obstructive pulmonary disease	0.000767	0.00294	CcSEcCtD
Trametinib—Urinary tract disorder—Salbutamol—chronic obstructive pulmonary disease	0.00076	0.00291	CcSEcCtD
Trametinib—Hypertension—Tiotropium—chronic obstructive pulmonary disease	0.000759	0.00291	CcSEcCtD
Trametinib—Cardiac disorder—Arformoterol—chronic obstructive pulmonary disease	0.000756	0.0029	CcSEcCtD
Trametinib—Cardiac disorder—Formoterol—chronic obstructive pulmonary disease	0.000756	0.0029	CcSEcCtD
Trametinib—Connective tissue disorder—Salbutamol—chronic obstructive pulmonary disease	0.000756	0.0029	CcSEcCtD
Trametinib—Infection—Aminophylline—chronic obstructive pulmonary disease	0.000756	0.0029	CcSEcCtD
Trametinib—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.000754	0.00289	CcSEcCtD
Trametinib—Urethral disorder—Salbutamol—chronic obstructive pulmonary disease	0.000754	0.00289	CcSEcCtD
Trametinib—Arthralgia—Tiotropium—chronic obstructive pulmonary disease	0.000748	0.00287	CcSEcCtD
Trametinib—Myalgia—Tiotropium—chronic obstructive pulmonary disease	0.000748	0.00287	CcSEcCtD
Trametinib—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.000746	0.00286	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.000743	0.00285	CcSEcCtD
Trametinib—Cardiac disorder—Montelukast—chronic obstructive pulmonary disease	0.000741	0.00284	CcSEcCtD
Trametinib—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000735	0.00281	CcSEcCtD
Trametinib—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000735	0.00281	CcSEcCtD
Trametinib—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.000732	0.0028	CcSEcCtD
Trametinib—Arrhythmia—Arformoterol—chronic obstructive pulmonary disease	0.000728	0.00279	CcSEcCtD
Trametinib—Arrhythmia—Formoterol—chronic obstructive pulmonary disease	0.000728	0.00279	CcSEcCtD
Trametinib—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.000725	0.00278	CcSEcCtD
Trametinib—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00072	0.00276	CcSEcCtD
Trametinib—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000719	0.00276	CcSEcCtD
Trametinib—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000719	0.00275	CcSEcCtD
Trametinib—Oedema—Tiotropium—chronic obstructive pulmonary disease	0.000718	0.00275	CcSEcCtD
Trametinib—Headache—Roflumilast—chronic obstructive pulmonary disease	0.000715	0.00274	CcSEcCtD
Trametinib—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.000714	0.00274	CcSEcCtD
Trametinib—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.000714	0.00274	CcSEcCtD
Trametinib—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.000714	0.00274	CcSEcCtD
Trametinib—Infection—Tiotropium—chronic obstructive pulmonary disease	0.000713	0.00273	CcSEcCtD
Trametinib—Malnutrition—Formoterol—chronic obstructive pulmonary disease	0.00071	0.00272	CcSEcCtD
Trametinib—Malnutrition—Arformoterol—chronic obstructive pulmonary disease	0.00071	0.00272	CcSEcCtD
Trametinib—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.000704	0.0027	CcSEcCtD
Trametinib—Cardiac failure congestive—Prednisolone—chronic obstructive pulmonary disease	0.000704	0.0027	CcSEcCtD
Trametinib—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.000699	0.00268	CcSEcCtD
Trametinib—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.000698	0.00267	CcSEcCtD
Trametinib—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000697	0.00267	CcSEcCtD
Trametinib—Dysgeusia—Formoterol—chronic obstructive pulmonary disease	0.000695	0.00266	CcSEcCtD
Trametinib—Dysgeusia—Arformoterol—chronic obstructive pulmonary disease	0.000695	0.00266	CcSEcCtD
Trametinib—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000694	0.00266	CcSEcCtD
Trametinib—Chills—Salbutamol—chronic obstructive pulmonary disease	0.000691	0.00265	CcSEcCtD
Trametinib—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.000688	0.00264	CcSEcCtD
Trametinib—Arrhythmia—Salbutamol—chronic obstructive pulmonary disease	0.000688	0.00263	CcSEcCtD
Trametinib—Back pain—Arformoterol—chronic obstructive pulmonary disease	0.000686	0.00263	CcSEcCtD
Trametinib—Back pain—Formoterol—chronic obstructive pulmonary disease	0.000686	0.00263	CcSEcCtD
Trametinib—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	0.000682	0.00261	CcSEcCtD
Trametinib—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	0.000682	0.00261	CcSEcCtD
Trametinib—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000678	0.0026	CcSEcCtD
Trametinib—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.000674	0.00258	CcSEcCtD
Trametinib—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.00067	0.00257	CcSEcCtD
Trametinib—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	0.000668	0.00256	CcSEcCtD
Trametinib—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000661	0.00253	CcSEcCtD
Trametinib—Dysgeusia—Salbutamol—chronic obstructive pulmonary disease	0.000656	0.00251	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000654	0.0025	CcSEcCtD
Trametinib—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000649	0.00249	CcSEcCtD
Trametinib—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.000648	0.00248	CcSEcCtD
Trametinib—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.000644	0.00247	CcSEcCtD
Trametinib—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000622	0.00238	CcSEcCtD
Trametinib—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000619	0.00237	CcSEcCtD
Trametinib—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000619	0.00237	CcSEcCtD
Trametinib—Cough—Formoterol—chronic obstructive pulmonary disease	0.000619	0.00237	CcSEcCtD
Trametinib—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000614	0.00235	CcSEcCtD
Trametinib—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000613	0.00235	CcSEcCtD
Trametinib—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000613	0.00235	CcSEcCtD
Trametinib—Cough—Montelukast—chronic obstructive pulmonary disease	0.000606	0.00232	CcSEcCtD
Trametinib—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000604	0.00231	CcSEcCtD
Trametinib—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000604	0.00231	CcSEcCtD
Trametinib—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000604	0.00231	CcSEcCtD
Trametinib—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000604	0.00231	CcSEcCtD
Trametinib—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000601	0.0023	CcSEcCtD
Trametinib—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000601	0.0023	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.0006	0.0023	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.0006	0.0023	CcSEcCtD
Trametinib—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000592	0.00227	CcSEcCtD
Trametinib—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000592	0.00227	CcSEcCtD
Trametinib—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000591	0.00226	CcSEcCtD
Trametinib—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000591	0.00226	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000588	0.00225	CcSEcCtD
Trametinib—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000587	0.00225	CcSEcCtD
Trametinib—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.000585	0.00224	CcSEcCtD
Trametinib—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000585	0.00224	CcSEcCtD
Trametinib—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000579	0.00222	CcSEcCtD
Trametinib—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000579	0.00222	CcSEcCtD
Trametinib—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000578	0.00222	CcSEcCtD
Trametinib—Infection—Formoterol—chronic obstructive pulmonary disease	0.000575	0.0022	CcSEcCtD
Trametinib—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000575	0.0022	CcSEcCtD
Trametinib—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.00057	0.00219	CcSEcCtD
Trametinib—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.00057	0.00219	CcSEcCtD
Trametinib—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000568	0.00218	CcSEcCtD
Trametinib—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000568	0.00218	CcSEcCtD
Trametinib—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000567	0.00217	CcSEcCtD
Trametinib—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000567	0.00217	CcSEcCtD
Trametinib—Infection—Montelukast—chronic obstructive pulmonary disease	0.000563	0.00216	CcSEcCtD
Trametinib—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000562	0.00215	CcSEcCtD
Trametinib—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000562	0.00215	CcSEcCtD
Trametinib—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000558	0.00214	CcSEcCtD
Trametinib—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000556	0.00213	CcSEcCtD
Trametinib—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000555	0.00213	CcSEcCtD
Trametinib—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000551	0.00211	CcSEcCtD
Trametinib—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000547	0.00209	CcSEcCtD
Trametinib—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000543	0.00208	CcSEcCtD
Trametinib—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000541	0.00207	CcSEcCtD
Trametinib—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000538	0.00206	CcSEcCtD
Trametinib—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000536	0.00205	CcSEcCtD
Trametinib—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000531	0.00203	CcSEcCtD
Trametinib—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000529	0.00202	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000528	0.00202	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000528	0.00202	CcSEcCtD
Trametinib—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000524	0.00201	CcSEcCtD
Trametinib—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000524	0.00201	CcSEcCtD
Trametinib—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000521	0.00199	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000517	0.00198	CcSEcCtD
Trametinib—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000513	0.00197	CcSEcCtD
Trametinib—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	0.000511	0.00196	CcSEcCtD
Trametinib—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000508	0.00194	CcSEcCtD
Trametinib—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000503	0.00193	CcSEcCtD
Trametinib—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.0005	0.00192	CcSEcCtD
Trametinib—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.0005	0.00192	CcSEcCtD
Trametinib—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000499	0.00191	CcSEcCtD
Trametinib—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000499	0.00191	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000498	0.00191	CcSEcCtD
Trametinib—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000495	0.0019	CcSEcCtD
Trametinib—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000495	0.0019	CcSEcCtD
Trametinib—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000495	0.00189	CcSEcCtD
Trametinib—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00049	0.00188	CcSEcCtD
Trametinib—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000489	0.00187	CcSEcCtD
Trametinib—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000484	0.00185	CcSEcCtD
Trametinib—Rash—Aminophylline—chronic obstructive pulmonary disease	0.00048	0.00184	CcSEcCtD
Trametinib—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000479	0.00184	CcSEcCtD
Trametinib—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000477	0.00183	CcSEcCtD
Trametinib—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000475	0.00182	CcSEcCtD
Trametinib—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000474	0.00182	CcSEcCtD
Trametinib—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000474	0.00181	CcSEcCtD
Trametinib—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000474	0.00181	CcSEcCtD
Trametinib—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000472	0.00181	CcSEcCtD
Trametinib—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000471	0.00181	CcSEcCtD
Trametinib—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000468	0.00179	CcSEcCtD
Trametinib—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000464	0.00178	CcSEcCtD
Trametinib—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000458	0.00175	CcSEcCtD
Trametinib—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000458	0.00175	CcSEcCtD
Trametinib—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000458	0.00175	CcSEcCtD
Trametinib—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000458	0.00175	CcSEcCtD
Trametinib—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000456	0.00175	CcSEcCtD
Trametinib—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000452	0.00173	CcSEcCtD
Trametinib—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000452	0.00173	CcSEcCtD
Trametinib—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000452	0.00173	CcSEcCtD
Trametinib—Headache—Tiotropium—chronic obstructive pulmonary disease	0.00045	0.00172	CcSEcCtD
Trametinib—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000449	0.00172	CcSEcCtD
Trametinib—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000448	0.00172	CcSEcCtD
Trametinib—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000448	0.00172	CcSEcCtD
Trametinib—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000447	0.00171	CcSEcCtD
Trametinib—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000444	0.0017	CcSEcCtD
Trametinib—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000441	0.00169	CcSEcCtD
Trametinib—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000432	0.00166	CcSEcCtD
Trametinib—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000432	0.00166	CcSEcCtD
Trametinib—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000426	0.00163	CcSEcCtD
Trametinib—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000425	0.00163	CcSEcCtD
Trametinib—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000422	0.00162	CcSEcCtD
Trametinib—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000415	0.00159	CcSEcCtD
Trametinib—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000415	0.00159	CcSEcCtD
Trametinib—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.00041	0.00157	CcSEcCtD
Trametinib—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.00041	0.00157	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000409	0.00157	CcSEcCtD
Trametinib—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000407	0.00156	CcSEcCtD
Trametinib—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000401	0.00154	CcSEcCtD
Trametinib—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000396	0.00152	CcSEcCtD
Trametinib—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000396	0.00152	CcSEcCtD
Trametinib—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000394	0.00151	CcSEcCtD
Trametinib—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000393	0.00151	CcSEcCtD
Trametinib—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000392	0.0015	CcSEcCtD
Trametinib—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000388	0.00149	CcSEcCtD
Trametinib—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000387	0.00148	CcSEcCtD
Trametinib—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.000384	0.00147	CcSEcCtD
Trametinib—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000383	0.00147	CcSEcCtD
Trametinib—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000383	0.00147	CcSEcCtD
Trametinib—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000375	0.00144	CcSEcCtD
Trametinib—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000375	0.00144	CcSEcCtD
Trametinib—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000374	0.00143	CcSEcCtD
Trametinib—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000368	0.00141	CcSEcCtD
Trametinib—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000368	0.00141	CcSEcCtD
Trametinib—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000365	0.0014	CcSEcCtD
Trametinib—Rash—Formoterol—chronic obstructive pulmonary disease	0.000365	0.0014	CcSEcCtD
Trametinib—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000365	0.0014	CcSEcCtD
Trametinib—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000365	0.0014	CcSEcCtD
Trametinib—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000363	0.00139	CcSEcCtD
Trametinib—Headache—Formoterol—chronic obstructive pulmonary disease	0.000363	0.00139	CcSEcCtD
Trametinib—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000362	0.00139	CcSEcCtD
Trametinib—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000362	0.00139	CcSEcCtD
Trametinib—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000361	0.00138	CcSEcCtD
Trametinib—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000361	0.00138	CcSEcCtD
Trametinib—Rash—Montelukast—chronic obstructive pulmonary disease	0.000358	0.00137	CcSEcCtD
Trametinib—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000357	0.00137	CcSEcCtD
Trametinib—Headache—Montelukast—chronic obstructive pulmonary disease	0.000355	0.00136	CcSEcCtD
Trametinib—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000348	0.00133	CcSEcCtD
Trametinib—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000345	0.00132	CcSEcCtD
Trametinib—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000344	0.00132	CcSEcCtD
Trametinib—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000344	0.00132	CcSEcCtD
Trametinib—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000344	0.00132	CcSEcCtD
Trametinib—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000343	0.00131	CcSEcCtD
Trametinib—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000337	0.00129	CcSEcCtD
Trametinib—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000332	0.00127	CcSEcCtD
Trametinib—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000327	0.00125	CcSEcCtD
Trametinib—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000325	0.00124	CcSEcCtD
Trametinib—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000322	0.00124	CcSEcCtD
Trametinib—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000321	0.00123	CcSEcCtD
Trametinib—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000315	0.00121	CcSEcCtD
Trametinib—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000314	0.0012	CcSEcCtD
Trametinib—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000303	0.00116	CcSEcCtD
Trametinib—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.0003	0.00115	CcSEcCtD
Trametinib—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000291	0.00111	CcSEcCtD
Trametinib—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000287	0.0011	CcSEcCtD
Trametinib—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000284	0.00109	CcSEcCtD
Trametinib—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000281	0.00108	CcSEcCtD
Trametinib—Erythema—Prednisone—chronic obstructive pulmonary disease	0.000279	0.00107	CcSEcCtD
Trametinib—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000279	0.00107	CcSEcCtD
Trametinib—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000263	0.00101	CcSEcCtD
Trametinib—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000258	0.000989	CcSEcCtD
Trametinib—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000241	0.000924	CcSEcCtD
Trametinib—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000238	0.000911	CcSEcCtD
Trametinib—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000238	0.000911	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000236	0.000904	CcSEcCtD
Trametinib—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000228	0.000873	CcSEcCtD
Trametinib—Infection—Prednisone—chronic obstructive pulmonary disease	0.000226	0.000867	CcSEcCtD
Trametinib—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000223	0.000856	CcSEcCtD
Trametinib—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000221	0.000848	CcSEcCtD
Trametinib—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.00022	0.000844	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000208	0.000795	CcSEcCtD
Trametinib—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000207	0.000794	CcSEcCtD
Trametinib—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000206	0.00079	CcSEcCtD
Trametinib—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000198	0.000759	CcSEcCtD
Trametinib—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000198	0.000757	CcSEcCtD
Trametinib—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000198	0.000757	CcSEcCtD
Trametinib—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000196	0.000753	CcSEcCtD
Trametinib—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000196	0.000753	CcSEcCtD
Trametinib—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000195	0.000747	CcSEcCtD
Trametinib—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000186	0.000714	CcSEcCtD
Trametinib—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000186	0.000714	CcSEcCtD
Trametinib—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.00018	0.00069	CcSEcCtD
Trametinib—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.00018	0.00069	CcSEcCtD
Trametinib—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000164	0.000626	CcSEcCtD
Trametinib—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000161	0.000618	CcSEcCtD
Trametinib—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000156	0.000597	CcSEcCtD
Trametinib—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000151	0.000577	CcSEcCtD
Trametinib—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000145	0.000555	CcSEcCtD
Trametinib—Rash—Prednisone—chronic obstructive pulmonary disease	0.000144	0.00055	CcSEcCtD
Trametinib—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000144	0.00055	CcSEcCtD
Trametinib—Headache—Prednisone—chronic obstructive pulmonary disease	0.000143	0.000547	CcSEcCtD
Trametinib—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000135	0.000519	CcSEcCtD
Trametinib—MAP2K1—Signaling by Interleukins—IL6—chronic obstructive pulmonary disease	0.000133	0.000544	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—TGFB1—chronic obstructive pulmonary disease	0.000133	0.000542	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 signaling—EGFR—chronic obstructive pulmonary disease	0.000133	0.000542	CbGpPWpGaD
Trametinib—MAP2K2—TGF-beta Signaling Pathway—TP53—chronic obstructive pulmonary disease	0.000133	0.000541	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—EGFR—chronic obstructive pulmonary disease	0.000132	0.000539	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—VEGFA—chronic obstructive pulmonary disease	0.000131	0.000535	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000131	0.000533	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—EGFR—chronic obstructive pulmonary disease	0.00013	0.000531	CbGpPWpGaD
Trametinib—MAP2K2—Toll Like Receptor 4 (TLR4) Cascade—IL6—chronic obstructive pulmonary disease	0.000129	0.000528	CbGpPWpGaD
Trametinib—MAP2K1—Activated TLR4 signalling—IL6—chronic obstructive pulmonary disease	0.000129	0.000525	CbGpPWpGaD
Trametinib—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000127	0.000518	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by VEGF—IL6—chronic obstructive pulmonary disease	0.000127	0.000518	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000126	0.000516	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—EGFR—chronic obstructive pulmonary disease	0.000126	0.000514	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by Insulin receptor—IL6—chronic obstructive pulmonary disease	0.000126	0.000514	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—EGFR—chronic obstructive pulmonary disease	0.000126	0.000512	CbGpPWpGaD
Trametinib—MAP2K1—EGF/EGFR Signaling Pathway—EGFR—chronic obstructive pulmonary disease	0.000126	0.000512	CbGpPWpGaD
Trametinib—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000125	0.000512	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—EGFR—chronic obstructive pulmonary disease	0.000125	0.00051	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—EGFR—chronic obstructive pulmonary disease	0.000125	0.00051	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—EGFR—chronic obstructive pulmonary disease	0.000125	0.00051	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—EGFR—chronic obstructive pulmonary disease	0.000125	0.000509	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—TGFB1—chronic obstructive pulmonary disease	0.000124	0.000507	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—EGFR—chronic obstructive pulmonary disease	0.000124	0.000507	CbGpPWpGaD
Trametinib—MAP2K1—TGF-beta Signaling Pathway—TP53—chronic obstructive pulmonary disease	0.000124	0.000506	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—TNF—chronic obstructive pulmonary disease	0.000124	0.000506	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—EGFR—chronic obstructive pulmonary disease	0.000124	0.000505	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—VEGFA—chronic obstructive pulmonary disease	0.000123	0.000501	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—EGFR—chronic obstructive pulmonary disease	0.000123	0.000501	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	0.000122	0.000499	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—EGFR—chronic obstructive pulmonary disease	0.000122	0.000499	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—EGFR—chronic obstructive pulmonary disease	0.000122	0.000497	CbGpPWpGaD
Trametinib—MAP2K1—Toll Like Receptor 4 (TLR4) Cascade—IL6—chronic obstructive pulmonary disease	0.000121	0.000494	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—EGFR—chronic obstructive pulmonary disease	0.000118	0.000482	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—EGFR—chronic obstructive pulmonary disease	0.000117	0.000477	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—EGFR—chronic obstructive pulmonary disease	0.000117	0.000477	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—EGFR—chronic obstructive pulmonary disease	0.000117	0.000477	CbGpPWpGaD
Trametinib—MAP2K2—Regulation of toll-like receptor signaling pathway—IL6—chronic obstructive pulmonary disease	0.000117	0.000475	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—TNF—chronic obstructive pulmonary disease	0.000116	0.000474	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—EGFR—chronic obstructive pulmonary disease	0.000116	0.000473	CbGpPWpGaD
Trametinib—MAP2K2—Toll-Like Receptors Cascades—IL6—chronic obstructive pulmonary disease	0.000115	0.00047	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by SCF-KIT—IL6—chronic obstructive pulmonary disease	0.000115	0.00047	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—APIP—chronic obstructive pulmonary disease	0.000115	0.000469	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—EGFR—chronic obstructive pulmonary disease	0.000115	0.000468	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—EGFR—chronic obstructive pulmonary disease	0.000114	0.000466	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—IL1B—chronic obstructive pulmonary disease	0.000114	0.000464	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—LEP—chronic obstructive pulmonary disease	0.000113	0.000462	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	0.000112	0.000458	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—ERBB3—chronic obstructive pulmonary disease	0.000112	0.000456	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—EGFR—chronic obstructive pulmonary disease	0.000111	0.000451	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—EGFR—chronic obstructive pulmonary disease	0.00011	0.000451	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—IL6—chronic obstructive pulmonary disease	0.00011	0.00045	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	0.00011	0.000449	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—TP53—chronic obstructive pulmonary disease	0.000109	0.000446	CbGpPWpGaD
Trametinib—MAP2K1—Regulation of toll-like receptor signaling pathway—IL6—chronic obstructive pulmonary disease	0.000109	0.000445	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB4—IL6—chronic obstructive pulmonary disease	0.000108	0.000443	CbGpPWpGaD
Trametinib—MAP2K1—Toll-Like Receptors Cascades—IL6—chronic obstructive pulmonary disease	0.000108	0.00044	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—IL6—chronic obstructive pulmonary disease	0.000108	0.00044	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	0.000107	0.000436	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—IL1B—chronic obstructive pulmonary disease	0.000106	0.000434	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—LEP—chronic obstructive pulmonary disease	0.000106	0.000432	CbGpPWpGaD
Trametinib—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000106	0.00043	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	0.000105	0.000427	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—ERBB3—chronic obstructive pulmonary disease	0.000105	0.000426	CbGpPWpGaD
Trametinib—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000104	0.000424	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—IL6—chronic obstructive pulmonary disease	0.000104	0.000423	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—EGFR—chronic obstructive pulmonary disease	0.000104	0.000422	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—IL6—chronic obstructive pulmonary disease	0.000103	0.000421	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—IL6—chronic obstructive pulmonary disease	0.000103	0.000421	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—IL6—chronic obstructive pulmonary disease	0.000103	0.000418	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000102	0.000418	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—TP53—chronic obstructive pulmonary disease	0.000102	0.000417	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—CRP—chronic obstructive pulmonary disease	0.000102	0.000417	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 signaling—IL6—chronic obstructive pulmonary disease	0.000102	0.000416	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—IL6—chronic obstructive pulmonary disease	0.000102	0.000414	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	0.0001	0.000408	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—TLR4—chronic obstructive pulmonary disease	9.79e-05	0.000399	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—IL6—chronic obstructive pulmonary disease	9.69e-05	0.000395	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—IL6—chronic obstructive pulmonary disease	9.65e-05	0.000393	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—IL6—chronic obstructive pulmonary disease	9.61e-05	0.000392	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—IL6—chronic obstructive pulmonary disease	9.61e-05	0.000392	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—IL6—chronic obstructive pulmonary disease	9.61e-05	0.000392	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—IL6—chronic obstructive pulmonary disease	9.6e-05	0.000392	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	9.58e-05	0.000391	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CRP—chronic obstructive pulmonary disease	9.56e-05	0.00039	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—IL6—chronic obstructive pulmonary disease	9.55e-05	0.00039	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—MMP9—chronic obstructive pulmonary disease	9.54e-05	0.000389	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—IL6—chronic obstructive pulmonary disease	9.52e-05	0.000388	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—IL6—chronic obstructive pulmonary disease	9.44e-05	0.000385	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—IL6—chronic obstructive pulmonary disease	9.39e-05	0.000383	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	9.24e-05	0.000377	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—TLR2—chronic obstructive pulmonary disease	9.23e-05	0.000377	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—TLR4—chronic obstructive pulmonary disease	9.16e-05	0.000374	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—IL6—chronic obstructive pulmonary disease	8.99e-05	0.000367	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—IL6—chronic obstructive pulmonary disease	8.99e-05	0.000367	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—IL6—chronic obstructive pulmonary disease	8.99e-05	0.000367	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—MMP9—chronic obstructive pulmonary disease	8.92e-05	0.000364	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—IL6—chronic obstructive pulmonary disease	8.91e-05	0.000363	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—IL6—chronic obstructive pulmonary disease	8.83e-05	0.00036	CbGpPWpGaD
Trametinib—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	8.8e-05	0.000359	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—IL6—chronic obstructive pulmonary disease	8.79e-05	0.000358	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	8.77e-05	0.000358	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—KL—chronic obstructive pulmonary disease	8.68e-05	0.000354	CbGpPWpGaD
Trametinib—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	8.68e-05	0.000354	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—TLR2—chronic obstructive pulmonary disease	8.64e-05	0.000352	CbGpPWpGaD
Trametinib—MAP2K2—Disease—HDAC2—chronic obstructive pulmonary disease	8.62e-05	0.000352	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—VEGFA—chronic obstructive pulmonary disease	8.56e-05	0.000349	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—EGFR—chronic obstructive pulmonary disease	8.51e-05	0.000347	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—IL6—chronic obstructive pulmonary disease	8.51e-05	0.000347	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	8.26e-05	0.000337	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	8.22e-05	0.000335	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	8.2e-05	0.000335	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	8.19e-05	0.000334	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—KL—chronic obstructive pulmonary disease	8.12e-05	0.000331	CbGpPWpGaD
Trametinib—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	8.09e-05	0.00033	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HDAC2—chronic obstructive pulmonary disease	8.07e-05	0.000329	CbGpPWpGaD
Trametinib—MAP2K2—Disease—KL—chronic obstructive pulmonary disease	8.02e-05	0.000327	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—VEGFA—chronic obstructive pulmonary disease	8.01e-05	0.000327	CbGpPWpGaD
Trametinib—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	7.98e-05	0.000325	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—EGFR—chronic obstructive pulmonary disease	7.97e-05	0.000325	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—IL6—chronic obstructive pulmonary disease	7.96e-05	0.000325	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	7.84e-05	0.00032	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	7.73e-05	0.000315	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—EGFR—chronic obstructive pulmonary disease	7.71e-05	0.000314	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	7.69e-05	0.000314	CbGpPWpGaD
Trametinib—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	7.67e-05	0.000313	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	7.61e-05	0.00031	CbGpPWpGaD
Trametinib—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	7.56e-05	0.000308	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	7.55e-05	0.000308	CbGpPWpGaD
Trametinib—MAP2K1—Disease—KL—chronic obstructive pulmonary disease	7.5e-05	0.000306	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GC—chronic obstructive pulmonary disease	7.4e-05	0.000302	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	7.33e-05	0.000299	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—EGFR—chronic obstructive pulmonary disease	7.21e-05	0.000294	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD8A—chronic obstructive pulmonary disease	7e-05	0.000285	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	6.88e-05	0.000281	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	6.86e-05	0.00028	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—MMP9—chronic obstructive pulmonary disease	6.8e-05	0.000278	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—IL6—chronic obstructive pulmonary disease	6.66e-05	0.000271	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD8A—chronic obstructive pulmonary disease	6.55e-05	0.000267	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—IL6—chronic obstructive pulmonary disease	6.54e-05	0.000267	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—ERBB3—chronic obstructive pulmonary disease	6.51e-05	0.000265	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	6.41e-05	0.000262	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—MMP9—chronic obstructive pulmonary disease	6.37e-05	0.00026	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—IL6—chronic obstructive pulmonary disease	6.23e-05	0.000254	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	6.17e-05	0.000252	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—IL6—chronic obstructive pulmonary disease	6.12e-05	0.00025	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	6.11e-05	0.000249	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—ERBB3—chronic obstructive pulmonary disease	6.09e-05	0.000248	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	6.04e-05	0.000246	CbGpPWpGaD
Trametinib—MAP2K2—Disease—ERBB3—chronic obstructive pulmonary disease	6.01e-05	0.000245	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CRP—chronic obstructive pulmonary disease	5.95e-05	0.000243	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—IL6—chronic obstructive pulmonary disease	5.92e-05	0.000242	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	5.72e-05	0.000233	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—TLR4—chronic obstructive pulmonary disease	5.7e-05	0.000233	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	5.65e-05	0.00023	CbGpPWpGaD
Trametinib—MAP2K1—Disease—ERBB3—chronic obstructive pulmonary disease	5.62e-05	0.000229	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KL—chronic obstructive pulmonary disease	5.61e-05	0.000229	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	5.61e-05	0.000229	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CRP—chronic obstructive pulmonary disease	5.57e-05	0.000227	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—IL6—chronic obstructive pulmonary disease	5.54e-05	0.000226	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—EGFR—chronic obstructive pulmonary disease	5.5e-05	0.000224	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	5.48e-05	0.000224	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—TLR4—chronic obstructive pulmonary disease	5.34e-05	0.000218	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KL—chronic obstructive pulmonary disease	5.25e-05	0.000214	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	5.25e-05	0.000214	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—TNF—chronic obstructive pulmonary disease	5.24e-05	0.000214	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	5.18e-05	0.000211	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—EGFR—chronic obstructive pulmonary disease	5.14e-05	0.00021	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NOS2—chronic obstructive pulmonary disease	5.01e-05	0.000204	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—TNF—chronic obstructive pulmonary disease	4.9e-05	0.0002	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—EGFR—chronic obstructive pulmonary disease	4.86e-05	0.000198	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	4.85e-05	0.000198	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NOS2—chronic obstructive pulmonary disease	4.69e-05	0.000191	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	4.63e-05	0.000189	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—EGFR—chronic obstructive pulmonary disease	4.54e-05	0.000185	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	4.33e-05	0.000177	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	4.24e-05	0.000173	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—IL6—chronic obstructive pulmonary disease	4.23e-05	0.000172	CbGpPWpGaD
Trametinib—MAP2K2—Disease—SERPINE1—chronic obstructive pulmonary disease	4.22e-05	0.000172	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	4.21e-05	0.000172	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.09e-05	0.000167	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	4.05e-05	0.000165	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.04e-05	0.000165	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NOS3—chronic obstructive pulmonary disease	4.03e-05	0.000164	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GCLC—chronic obstructive pulmonary disease	4e-05	0.000163	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	3.97e-05	0.000162	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	3.96e-05	0.000162	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—IL6—chronic obstructive pulmonary disease	3.95e-05	0.000161	CbGpPWpGaD
Trametinib—MAP2K1—Disease—SERPINE1—chronic obstructive pulmonary disease	3.95e-05	0.000161	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	3.94e-05	0.000161	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	3.79e-05	0.000155	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NOS3—chronic obstructive pulmonary disease	3.77e-05	0.000154	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	3.76e-05	0.000154	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—IL6—chronic obstructive pulmonary disease	3.73e-05	0.000152	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	3.73e-05	0.000152	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL1B—chronic obstructive pulmonary disease	3.71e-05	0.000151	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.69e-05	0.000151	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CTGF—chronic obstructive pulmonary disease	3.65e-05	0.000149	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	3.52e-05	0.000144	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—IL6—chronic obstructive pulmonary disease	3.49e-05	0.000142	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL1B—chronic obstructive pulmonary disease	3.47e-05	0.000142	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.36e-05	0.000137	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.1e-05	0.000126	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.95e-05	0.00012	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	2.9e-05	0.000118	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EGFR—chronic obstructive pulmonary disease	2.83e-05	0.000115	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.82e-05	0.000115	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.8e-05	0.000114	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.77e-05	0.000113	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.76e-05	0.000113	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TGFB1—chronic obstructive pulmonary disease	2.66e-05	0.000109	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EGFR—chronic obstructive pulmonary disease	2.65e-05	0.000108	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.64e-05	0.000108	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EGFR—chronic obstructive pulmonary disease	2.61e-05	0.000107	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.58e-05	0.000105	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.5e-05	0.000102	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TGFB1—chronic obstructive pulmonary disease	2.49e-05	0.000102	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EGFR—chronic obstructive pulmonary disease	2.44e-05	9.96e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.44e-05	9.96e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.38e-05	9.7e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.34e-05	9.55e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.26e-05	9.23e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.23e-05	9.08e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL6—chronic obstructive pulmonary disease	2.17e-05	8.87e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.17e-05	8.85e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	2.15e-05	8.75e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.12e-05	8.64e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL6—chronic obstructive pulmonary disease	2.03e-05	8.29e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.03e-05	8.29e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—IL6—chronic obstructive pulmonary disease	2.01e-05	8.19e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	1.96e-05	7.99e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.9e-05	7.75e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—IL6—chronic obstructive pulmonary disease	1.88e-05	7.66e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.87e-05	7.61e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.83e-05	7.46e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.8e-05	7.36e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.74e-05	7.12e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.71e-05	6.98e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ALB—chronic obstructive pulmonary disease	1.66e-05	6.77e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—NOS3—chronic obstructive pulmonary disease	1.59e-05	6.48e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.54e-05	6.26e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.5e-05	6.14e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.48e-05	6.05e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.44e-05	5.86e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.41e-05	5.73e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.38e-05	5.64e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.31e-05	5.36e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.31e-05	5.35e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	8.91e-06	3.63e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	8.52e-06	3.48e-05	CbGpPWpGaD
